Skip to main content
NONOF logo

Novo Nordisk A/S (NONOF) Stock Price & Analysis

Novo Nordisk A/S (NONOF) — price $39.50 (-0.10%), as of the Nov 19, 2026 trading session; market cap $174B.

Educational signal · not a buy or sell recommendation · How to read this

$39.50 −$0.04 (-0.10%) Market Cap $174B

Novo Nordisk A/S · NONOF · Healthcare · Drug Manufacturers - General

Novo Nordisk A/S operates as a prominent global pharmaceutical firm, dedicated to the discovery, development, production, and distribution of a wide array of medicinal products.

Price as of Nov 19, 2026

Key Statistics

No MoonshotScore yet: we have not published a score for this company.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • PFE · Pfizer Inc. · 67 /100
  • GILD · Gilead Sciences, Inc. · 72 /100
  • AMGN · Amgen Inc. · 84 /100

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$39.50
Change on the day-0.10%
52-week range$34.00–$64.75
Market capitalisation$174B—
Price / earnings (trailing)10.80
Shares traded on the day3.1K
Beta (volatility vs the S&P 500)0.35

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 19, 2026: low $35, high $63, latest $40. $63 $35 high $63 Oct 17, 2025 Nov 19, 2026 · $40 $55Oct 17, 2025$49Oct 31, 2025$48Nov 14, 2025$47Nov 28, 2025$51Dec 12, 2025$52Dec 26, 2025$59Jan 9, 2026$63Jan 23, 2026$48Feb 6, 2026$48Feb 20, 2026$38Mar 6, 2026$36Mar 20, 2026$36Apr 2, 2026$38Apr 17, 2026$43May 1, 2026$45May 15, 2026$45May 29, 2026$44Jun 12, 2026$48Jun 26, 2026$48Jul 10, 2026$50Jul 24, 2026$47Aug 7, 2026$47Aug 21, 2026$46Sep 4, 2026$43Sep 18, 2026$37Oct 2, 2026$39Oct 16, 2026$39Oct 30, 2026$41Nov 13, 2026

Point at or tab to any week for its close.

Other perspectives

Council score for Novo Nordisk A/S (NONOF): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

6 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Favorable read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Favorable read
Moon AI lens (model) Favorable read

Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Moderate
Margin of Safety Fairly Valued
Profit Margin Strong
Revenue Growth Neutral
Debt/Equity Weak
ROE Strong
Gross Margin Strong

Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 11, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Novo Nordisk A/S (NONOF), and what does it report?

Short answer

Novo Nordisk A/S operates as a prominent global pharmaceutical firm, dedicated to the discovery, development, production, and distribution of a wide array of medicinal products. Healthcare / Drug Manufacturers General SEC filing business address: Novo Alle DK 2880, Bagsvaerd Denmark, G7, 00000. It employs 68,794 people and is led by Maziar Mike Doustdar. In Q3 FY2026 it reported revenue of kr77.30B and net income of kr16.34B. The market values it at $174B.

2 · Latest results

What do the latest results show for Novo Nordisk A/S (NONOF)?

Short answer · as of

The most recent reported quarter, Q3 FY2026, carried revenue of kr77.30B. Against analyst estimates the company has EPS beat 6 of the last 8 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q3 FY2026kr77.30Bkr16.34Bkr3.68 (diluted)
Q2 FY2026kr78.49Bkr20.99Bkr4.74 (diluted)
Q1 FY2026kr96.82Bkr48.56Bkr10.91 (diluted)
Q4 FY2025kr78.96Bkr26.83Bkr6.03 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Novo Nordisk A/S (NONOF)?

Short answer · as of

The distress and quality screens read Altman Z 3.77 · Piotroski F 7. Trailing ratios: ROE 58.4% · ROA 19.1% · current ratio 0.84.

The records behind this page

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held NONOF in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported NONOF in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

Common Questions About NONOF (Healthcare)

Research dated 2026-09-12; the full attribution is under Sources. The last question is answered from this page's own dated data, not from the research.

Does Novo Nordisk sell medicines outside diabetes and obesity care?

Its Biopharmaceuticals division sells specialized treatments for hemophilia, growth disorders and hormone replacement. Those products sit beside the larger chronic-care portfolio and its delivery systems.

What is the NONOF stock price today?

The last price recorded for Novo Nordisk A/S (NONOF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 19 figures on this page — 1 from SEC filings and earnings calls, 15 from Financial Modeling Prep (FMP) and 3 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-12), by section of the research

  • FAQ: Does Novo Nordisk sell medicines outside diabetes and obesity care?: Business description
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.